The iv infusion Bevacimab contains Bevacizumab and is made by Healthcare Pharmaceuticals Ltd. It is often given together with chemotherapy as part of a wider treatment plan.
There are 12 brands of Bevacizumab listed in Bangladesh. 2 of them have a lower unit price than Bevacimab. The lowest listed price is Bevastim 100 mg/4 ml IV Infusion at ৳ 13925.00 per unit.
What is Bevacimab 100 mg/4 ml IV Infusion?
The iv infusion Bevacimab contains Bevacizumab and is made by Healthcare Pharmaceuticals Ltd. It is given as an intravenous infusion in a clinical setting. This interaction is linked to endothelial cell growth and the formation of new blood vessels. The doctor decides the dose and course, and treatment is supervised by a cancer specialist.
Uses of Bevacimab
It is often given together with chemotherapy as part of a wider treatment plan. It is used as part of a wider treatment plan chosen by the cancer specialist, often alongside other cancer medicines. Bevacizumab is used in the treatment of several cancers. Your doctor will decide if it is suitable for you.
How to use Bevacimab
Bevacimab is given as an intravenous infusion by a healthcare professional, usually in a hospital or cancer treatment setting. Take Bevacimab as your doctor tells you. The doctor decides the dose, the schedule and how long treatment continues, based on the type of cancer and other medicines being used.
Side effects of Bevacimab
Some people may notice side effects during or after treatment with Bevacimab. Reported effects include dry mouth, cough, voice changes, loss of appetite, diarrhoea, nausea, vomiting, constipation, mouth sores, headache, back pain and cold-like symptoms such as a stuffy nose, sneezing or sore throat. Contact your doctor if you notice anything unusual after taking it. Tell your doctor or nurse about any side effect, especially if it bothers you or does not settle.
Safety and precautions
Bevacimab is given under specialist supervision, and the doctor decides whether it is suitable for you. The risk of certain blood vessel problems during treatment is increased in people with a history of arterial thromboembolism, diabetes, or older age; discuss your history with your doctor. Always ask your doctor or pharmacist about any concerns. Tell your doctor about all the other medicines you take.
Frequently asked questions
What is Bevacimab used for?
It is often given together with chemotherapy as part of a wider treatment plan. It is used as part of a wider treatment plan chosen by the cancer specialist, often alongside other cancer medicines.
How do I use Bevacimab correctly?
Bevacimab is given as an intravenous infusion by a healthcare professional, usually in a hospital or cancer treatment setting. Take Bevacimab as your doctor tells you.
What should I watch for while using Bevacimab?
Some people may notice side effects during or after treatment with Bevacimab. Reported effects include dry mouth, cough, voice changes, loss of appetite, diarrhoea, nausea, vomiting, constipation, mouth sores, headache, back pain and cold-like symptoms such as a stuffy nose, sneezing or sore throat.
Persistent, Recurrent, or Metastatic Carcinoma of the Cervix
Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Pharmacology
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.
Dosage & Administration
Metastatic Colorectal Cancer (mCRC): The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy.
Administer 5 mg/kg when used in combination with bolus-IFL.
Administer 10 mg/kg when used in combination with FOLFOX4.
Administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Bevacizumab-containing regimen.
Non-Squamous Non-Small Cell Lung Cancer (NSCLC): The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel.
Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks.
Metastatic Renal Cell Carcinoma (mRCC): The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa.
Cervical Cancer: The recommended dose of Bevacizumab is 15 mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan.
Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The recommended dose is 10mg/ kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks).
Interaction
A drug interaction study was performed in which irinotecan was administered as part of the FOLFIRI regimen with or without Bevacizumab. The results demonstrated no significant effect of Bevacizumab on the pharmacokinetics of irinotecan or its active metabolite SN38.
In a randomized study in 99 patients with NSCLC, based on limited data, there did not appear to be a difference in the mean exposure of either carboplatin or paclitaxel when each was administered alone or in combination with Bevacizumab. However, 3 of the 8 patients receiving Bevacizumab plus paclitaxel/carboplatin had substantially lower paclitaxel exposure after four cycles of treatment (at Day 63) than those at Day 0, while patients receiving paclitaxel/carboplatin without Bevacizumab had a greater paclitaxel exposure at Day 63 than at Day 0.
Contraindications
There are no contraindications listed in the manufacturer’s labeling.
Side Effects
dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection.
Pregnancy & Lactation
Pregnancy Category C. There are no adequate or well controlled studies of bevacizumab in pregnant women. It is not known whether Avastin is secreted in human milk.
Precautions & Warnings
Arterial Thromboembolic Events. Among patients receiving Bevacizumab in combination with chemotherapy, the risk of developing ATE during therapy was increased in patients with a history of arterial thromboembolism, diabetes, or age greater than 65
Overdose Effects
The highest dose tested in humans (20 mg/kg IV) was associated with headache in nine of 16 patients and with severe headache in three of 16 patients.
Storage Conditions
Bevacizumab vials are stable at 2 to 8° C. Bevacizumab vials should be protected from light. Do not freeze or shake. Diluted Bevacizumab solutions may be stored at 2 to 8° C for up to 8 hours. Store in the original carton until time of use. No incompatibilities between Bevacizumab and polyvinylchloride or polyolefin bags have been observed.
Alternative brands of Bevacizumab
Other brands with the same generic name, cheapest first.